<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200118">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485134</url>
  </required_header>
  <id_info>
    <org_study_id>NMRC.2006.0007</org_study_id>
    <secondary_id>A-14057</secondary_id>
    <secondary_id>WRAIR 1328</secondary_id>
    <nct_id>NCT00485134</nct_id>
  </id_info>
  <brief_title>Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Office of the Surgeon General</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Walter Reed Army Institute of Research (WRAIR)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select a safe and immunogenic dose of Invaplex 50 intranasal
      vaccine, and to assess protection of Invaplex 50 intranasal vaccine against diarrhea,
      dysentery, and fever following challenge with the Shigella flexneri 2a 2457T strain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Shigellosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Invaplex 50 Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of
             enrollment.

          -  Completion and review of comprehension test (achieved ≥ 70% accuracy).

          -  Signed informed consent form.

          -  Available for the required follow-up period and scheduled clinic visits.

          -  Women: negative pregnancy test with understanding (through informed consent process)
             to not become pregnant during the study or within two (2) months following study
             completion.

        Exclusion Criteria:

        General Health

          -  Health problems affecting study participation from medical history specifically to
             include chronic medical conditions such as psychiatric conditions, diabetes mellitus
             and hypertension or any other condition requiring chronic daily therapy that would
             place the volunteer at increased risk - as determined by a study physician, current
             use of antihypertensive medications, or other medications that may interact with
             pseudoephedrine in the event it is required to treat rhinorrhea).

          -  Clinically significant abnormalities on physical examination.

          -  Use of immunosuppressive drugs such as corticosteroids or chemotherapeutics that may
             influence antibody development.

          -  Women currently nursing

          -  Participation in research involving another investigational product (defined as
             receipt of investigational product or exposure to invasive investigational device) 30
             days before planned date of first vaccination or anytime throughout the duration of
             the study.

          -  Positive blood test for HBsAG, HCV, HIV-1.

          -  Clinically significant abnormalities on basic laboratory screening.

          -  Immunosuppressive illness or IgA deficiency (below the normal limits).

        Research specific

          -  Presence of nasal polyps, ulcers, or deviated nasal septum (further defined in
             section 4.2).

          -  History of chronic sinusitis or chronic/seasonal rhinitis (further defined in section
             4.2)

          -  History of rhinoplasty.

          -  History of reactive airway disease (asthma), chronic obstructive pulmonary disease,
             or chronic bronchitis.

          -  History of Bell's palsy.

          -  Current smoker or smoker in past 3 months ('smoker' defined as daily cigarette cigar,
             or pipe use for a period of at least 1 month).

          -  Regular use (weekly or more often of antidiarrheal, anti-constipation, or antacid
             therapy

          -  Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day)
             on a regular basis; loose or liquid stools on other than an occasional basis.

          -  Personal or family history of an inflammatory arthritis.

          -  Positive blood test for HLA-B27.

          -  Prior exposure to Shigella

          -  History of microbiologically confirmed Shigella infection.

          -  Received previous experimental Shigella vaccine or live Shigella challenge.

          -  Travel to countries where Shigella or other enteric infections are endemic (most of
             the developing world) within two years prior to dosing.

          -  Occupation involving handling of Shigella bacteria currently, or in the past 3 years.

          -  Serum IgG titer ≥ 2500 to Shigella LPS

        Additionally, subjects participating in stage 2 with any of the following will be
        excluded:

          -  Are employed as a food handler, daycare provider or work in a nursing home, or are in
             direct care of an immunocompromised person, a child &lt;2 years of age or frail elderly.

          -  Significant abnormalities in pre-admission screening lab hematology, serum chemistry,
             urinalysis or EKG (EKG only in volunteers ≥40 years), as determined by PI or the PI
             in consultation with the medical monitor and sponsor.

          -  Allergy to ciprofloxacin on ampicillin (excluded if allergic to either).

          -  History of diarrhea in the 2 weeks prior to planned inpatient phase.

          -  Use of antibiotics during the 7 days before Shigella inoculation or proton pump
             inhibitors, H2 blockers, or antacids within 48 hours of inoculation.

          -  Inability to comply with inpatient rules and regulations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Riddle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naval Medical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Immunization Research (CIR) John Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Trials, WRAIR</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 1, 2010</lastchanged_date>
  <firstreceived_date>June 11, 2007</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
